Company Overview and News

1
China's HNA group chairman Wang Jian dies from 15 metre fall while posing for photo in France

2018-07-04 abc.net.au
The co-chairman of HNA Group, a conglomerate that operates China's fourth-largest airline and finance, logistics and other businesses around the world, died in an accident while on a business trip in France, the company said.
VBHLF DB VAH VBHLY HLT

0
RPT-Airlines take aim at Australia's airport privatisation model

2018-06-04 reuters
SYDNEY, June 4 (Reuters) - As more countries look to privatise airports two conflicting narratives have taken wing: airlines point to Australia’s big city airports as a cautionary tale of light regulation, while airports say they’ve found a winning formula for governments, investors and passengers.
VBHLF VAH VBHLY

0
Airlines take aim at Australia's airport privatization model

2018-06-01 reuters
SYDNEY (Reuters) - As more countries look to privatize airports two conflicting narratives have taken wing: airlines point to Australia’s big city airports as a cautionary tale of light regulation, while airports say they’ve found a winning formula for governments, investors and passengers.
VBHLF VAH VBHLY

0
Airline under China's HNA Group is raising funds ahead of a planned IPO

2018-05-30 cnbc
Chinese conglomerate HNA Group's Hong Kong Airlines is considering an initial public offering in the "short to medium term" and tapping investors to raise funds through the issue of new shares and convertible bonds, a document reviewed by Reuters shows.
VBHLF VAH VBHLY CPCAY 0293 CPCAF

12
Shares up on A2 Milk bounce-back, Air NZ and Synlait gain

2018-04-04 nzherald.co.nz
New Zealand shares surged on A2 Milk Co's recovery from last week's selling, while Air New Zealand gained on news it will ditch an alliance with Virgin Australia.
VBHLF FBU FBU ANZLY VAH AIR VBHLY FCREY ANZFF ANZFY FRCEF AIZ

6
Virgin Australia receives notice of Air New Zealand's intention to end alliance - Channel NewsAsia

2018-04-04 channelnewsasia
Virgin Australia Holdings Ltd said on Wednesday it received a notice from Air New Zealand regarding the termination of the airlines' strategic alliance.
VBHLF ANZLY VAH AIR VBHLY ANZFF ANZFY AIZ

6
Virgin Australia receives notice of Air New Zealand's intention to end alliance

2018-04-04 reuters
(Reuters) - Virgin Australia Holdings Ltd (VAH.AX) said on Wednesday it received a notice from Air New Zealand (AIR.NZ) regarding the termination of the airlines’ strategic alliance.
VBHLF ANZLY VAH AIR VBHLY ANZFF ANZFY AIZ

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...